Patents Granted to Two Formerly Secret Inventions
Two patent applications that had been subject to “secrecy orders” under the Invention Secrecy Act for years or decades were finally granted patents and publicly disclosed in 2016.
“Only two patents have been granted so far on cases in which the secrecy order was rescinded in FY16,” the US Patent and Trademark Office said this week in response to a Freedom of Information Act request. They were among the 20 inventions whose secrecy orders were rescinded over the past year.
One of the patents concerns “a controllable barrier layer against electromagnetic radiation, to be used, inter alia, as a radome for a radar antenna for instance.” The inventor, Anders Grop of Sweden, filed the patent application in 2007 and it was granted on April 5, 2016 (patent number 9,306,290).
The other formerly secret invention that finally received a patent this year described “multi-charge munitions, incorporating hole-boring charge assemblies.” Detonation of the munitions is “suitable for defeating a concrete target.” That invention was originally filed in 1990 by Kevin Mark Powell and Edward Evans of the United Kingdom and was granted on October 25, 2016 (patent number 9,476,682).
The inventors could not immediately be contacted for comment. But judging from appearances, the decision to control the disclosure of these two inventions for a period of time and then to grant them a patent was consistent with the terms of the Invention Secrecy Act, and it had no obvious adverse impacts.
Commercial artificial intelligence tools have recently emerged that are able to produce police reports. If the resulting reports are inaccurate, incomplete or biased, or if the process leaks confidential information, this could undermine the criminal justice system and harm citizens.
Too often, affected patients, clinicians, and regulators cannot see how the system works, why a decision was made, or whether meaningful human oversight occurred.
Existing tools from other domains, such as existing robust public engagement processes in drug development, when applied to AI deployment can help strengthen public trust in these systems and enhance perceptions of their legitimacy and the decisions they produce.
With thoughtful policy action, it is still possible to build systems that are fair, transparent, and accountable, and to earn the public trust that will ultimately determine AI’s future. We hope policymakers are ready to act.